Viking Therapeutics, Inc

VKTXNasdaqCIK 1607678Healthcare / Drug Manufacturersfiscal year ends December51 quarters since 2014

Revenue, Q3 FY2026
$0
no year-earlier figure
Net income
−$183M
−101.8% on Q3 FY2025
Free cash flow
—
no year-earlier figure
Diluted EPS
$-1.55
−91.4% on Q3 FY2025
Revenue, TTM
$0
trailing four quarters
Net margin, TTM
—
net income −$627M
Free cash flow, TTM
—
Cash and equivalents
$678M
long-term debt —, Sep 30, 2026
Shares, 12-month change
+12.8%
128M shares, Sep 30, 2026, split-adjusted
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$3.7B
at the close, buybacks

Latest quarter Q3 FY2026, filed October 29, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Viking Therapeutics, Inc reported revenue of $0, and net loss of $183M (−101.8%). Diluted earnings per share were $-1.55.

Share price

Daily candlesticks from November 18, 2024 to November 13, 2026, with each earnings release marked; a release after the close marks the day it came out, so its reaction is the next candle. See this earnings season for every company’s reaction.

VKTX daily priceSplit-adjusted, US dollars; an earnings release
Nov 13, 2026O $27.44 · H $29.96 · L $26.69 · C $29.22 · +5.95% on the dayOver the range: −25.08%, Nov 14, 2025 to Nov 13, 2026
$23$28$33$39$44Nov 25Jan 26Apr 26Jun 26Sep 26Nov 26

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of October 29, 2026.

Revenue and net incomeRevenueNet income
−$200M−$150M−$100M−$50M$0$50MQ4'22, Revenue: $0Q4'22, Net income: −$20MQ4'22Q1'23, Revenue: $0Q1'23, Net income: −$20MQ1'23Q2'23, Revenue: $0Q2'23, Net income: −$19MQ2'23Q3'23, Revenue: $0Q3'23, Net income: −$23MQ3'23Q4'23, Revenue: $0Q4'23, Net income: −$25MQ4'23Q1'24, Revenue: $0Q1'24, Net income: −$27MQ1'24Q2'24, Revenue: $0Q2'24, Net income: −$22MQ2'24Q3'24, Revenue: $0Q3'24, Net income: −$25MQ3'24Q4'24, Revenue: $0Q4'24, Net income: −$35MQ4'24Q1'25, Revenue: $0Q1'25, Net income: −$46MQ1'25Q2'25, Revenue: $0Q2'25, Net income: −$66MQ2'25Q3'25, Revenue: $0Q3'25, Net income: −$91MQ3'25Q4'25, Revenue: $0Q4'25, Net income: −$158MQ4'25Q1'26, Revenue: $0Q1'26, Net income: −$158MQ1'26Q2'26, Revenue: $0Q2'26, Net income: −$128MQ2'26Q3'26, Revenue: $0Q3'26, Net income: −$183MQ3'26−$200M−$150M−$100M−$50M$0$50MQ4'22, Revenue: $0Q4'22, Net income: −$20MQ4'22Q1'23, Revenue: $0Q1'23, Net income: −$20MQ1'23Q2'23, Revenue: $0Q2'23, Net income: −$19MQ2'23Q3'23, Revenue: $0Q3'23, Net income: −$23MQ3'23Q4'23, Revenue: $0Q4'23, Net income: −$25MQ4'23Q1'24, Revenue: $0Q1'24, Net income: −$27MQ1'24Q2'24, Revenue: $0Q2'24, Net income: −$22MQ2'24Q3'24, Revenue: $0Q3'24, Net income: −$25MQ3'24Q4'24, Revenue: $0Q4'24, Net income: −$35MQ4'24Q1'25, Revenue: $0Q1'25, Net income: −$46MQ1'25Q2'25, Revenue: $0Q2'25, Net income: −$66MQ2'25Q3'25, Revenue: $0Q3'25, Net income: −$91MQ3'25Q4'25, Revenue: $0Q4'25, Net income: −$158MQ4'25Q1'26, Revenue: $0Q1'26, Net income: −$158MQ1'26Q2'26, Revenue: $0Q2'26, Net income: −$128MQ2'26Q3'26, Revenue: $0Q3'26, Net income: −$183MQ3'26−$200M−$150M−$100M−$50M$0$50MQ4'22, Revenue: $0Q4'22, Net income: −$20MQ1'23, Revenue: $0Q1'23, Net income: −$20MQ1'23Q2'23, Revenue: $0Q2'23, Net income: −$19MQ3'23, Revenue: $0Q3'23, Net income: −$23MQ3'23Q4'23, Revenue: $0Q4'23, Net income: −$25MQ1'24, Revenue: $0Q1'24, Net income: −$27MQ1'24Q2'24, Revenue: $0Q2'24, Net income: −$22MQ3'24, Revenue: $0Q3'24, Net income: −$25MQ3'24Q4'24, Revenue: $0Q4'24, Net income: −$35MQ1'25, Revenue: $0Q1'25, Net income: −$46MQ1'25Q2'25, Revenue: $0Q2'25, Net income: −$66MQ3'25, Revenue: $0Q3'25, Net income: −$91MQ3'25Q4'25, Revenue: $0Q4'25, Net income: −$158MQ1'26, Revenue: $0Q1'26, Net income: −$158MQ1'26Q2'26, Revenue: $0Q2'26, Net income: −$128MQ3'26, Revenue: $0Q3'26, Net income: −$183MQ3'26

Net income losses drawn in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$200M$400M$600M$800MQ4'22, Cash and equivalents: $37MQ4'22Q1'23, Cash and equivalents: $18MQ1'23Q2'23, Cash and equivalents: $70MQ2'23Q3'23, Cash and equivalents: $37MQ3'23Q4'23, Cash and equivalents: $56MQ4'23Q1'24, Cash and equivalents: $196MQ1'24Q2'24, Cash and equivalents: $44MQ2'24Q3'24, Cash and equivalents: $50MQ3'24Q4'24, Cash and equivalents: $27MQ4'24Q1'25, Cash and equivalents: $38MQ1'25Q2'25, Cash and equivalents: $34MQ2'25Q3'25, Cash and equivalents: $100MQ3'25Q4'25, Cash and equivalents: $166MQ4'25Q1'26, Cash and equivalents: $118MQ1'26Q2'26, Cash and equivalents: $126MQ2'26Q3'26, Cash and equivalents: $678MQ3'26$0$200M$400M$600M$800MQ4'22, Cash and equivalents: $37MQ4'22Q1'23, Cash and equivalents: $18MQ1'23Q2'23, Cash and equivalents: $70MQ2'23Q3'23, Cash and equivalents: $37MQ3'23Q4'23, Cash and equivalents: $56MQ4'23Q1'24, Cash and equivalents: $196MQ1'24Q2'24, Cash and equivalents: $44MQ2'24Q3'24, Cash and equivalents: $50MQ3'24Q4'24, Cash and equivalents: $27MQ4'24Q1'25, Cash and equivalents: $38MQ1'25Q2'25, Cash and equivalents: $34MQ2'25Q3'25, Cash and equivalents: $100MQ3'25Q4'25, Cash and equivalents: $166MQ4'25Q1'26, Cash and equivalents: $118MQ1'26Q2'26, Cash and equivalents: $126MQ2'26Q3'26, Cash and equivalents: $678MQ3'26$0$200M$400M$600M$800MQ4'22, Cash and equivalents: $37MQ1'23, Cash and equivalents: $18MQ1'23Q2'23, Cash and equivalents: $70MQ3'23, Cash and equivalents: $37MQ3'23Q4'23, Cash and equivalents: $56MQ1'24, Cash and equivalents: $196MQ1'24Q2'24, Cash and equivalents: $44MQ3'24, Cash and equivalents: $50MQ3'24Q4'24, Cash and equivalents: $27MQ1'25, Cash and equivalents: $38MQ1'25Q2'25, Cash and equivalents: $34MQ3'25, Cash and equivalents: $100MQ3'25Q4'25, Cash and equivalents: $166MQ1'26, Cash and equivalents: $118MQ1'26Q2'26, Cash and equivalents: $126MQ3'26, Cash and equivalents: $678MQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

Viking Therapeutics, Inc income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Jul 29, 2026Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 11, 2026Q3 FY2025ended Sep 30, 2025filed Oct 23, 2025Q2 FY2025ended Jun 30, 2025filed Jul 23, 2025Q1 FY2025ended Mar 31, 2025filed Apr 24, 2025Q4 FY2024ended Dec 31, 2024filed Feb 26, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue00000000—
Cost of revenue—————————
Gross profit—————————
Research and development16711615015390604131+85.4%
Selling, general and administrative201714119141415+135.9%
Operating income(187)(133)(164)(165)(99)(75)(55)(46)−89.8%
Other income (expense)4567891011−49.5%
Pretax income—————————
Income tax—————————
Net income(183)(128)(158)(158)(91)(66)(46)(35)−101.8%
Diluted EPS ($)(1.55)(1.10)(1.37)—(0.81)(0.58)(0.41)—−91.4%
Diluted shares (millions)118116116—112112112——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

Viking Therapeutics, Inc balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Jul 29, 2026Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 11, 2026Q3 FY2025ended Sep 30, 2025filed Oct 23, 2025Q2 FY2025ended Jun 30, 2025filed Jul 23, 2025Q1 FY2025ended Mar 31, 2025filed Apr 24, 2025Q4 FY2024ended Dec 31, 2024filed Feb 26, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents678126118166100343827+575.1%
Short-term investments282376485540614774814876−54.1%
Total current assets973518608716739827866907+31.7%
Total assets977522608716739828867908+32.2%
Total current liabilities1341101067726322027+413.7%
Long-term debt—————————
Total debt—————————
Total liabilities3891141067726322028+1372.7%
Stockholders’ equity589408502639713795847880−17.5%
Shares outstanding (millions)128117116116113112112112—

Positions at each period end. Long-term debt is the line the filer tags, with or without its current portion. Total debt is one definition across filers, built from filed lines: long-term debt with its current portion plus short-term borrowings, finance leases where the filer folds them into its debt line, operating leases never; it is blank where the tags do not add up to it. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

Viking Therapeutics, Inc cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Jul 29, 2026Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 11, 2026Q3 FY2025ended Sep 30, 2025filed Oct 23, 2025Q2 FY2025ended Jun 30, 2025filed Jul 23, 2025Q1 FY2025ended Mar 31, 2025filed Apr 24, 2025Q4 FY2024ended Dec 31, 2024filed Feb 26, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow(138)(125)(114)(85)(94)(47)(52)(31)−47.0%
Capital expenditures—————————
Free cash flow (CFO − capex)—————————
Depreciation and amortization—————————
Share repurchases—————————
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 11, 2026.

Income statement

Viking Therapeutics, Inc income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 11, 2026FY2024ended Dec 31, 2024filed Feb 26, 2025FY2023ended Dec 31, 2023filed Feb 7, 2024FY2022ended Dec 31, 2022filed Feb 10, 2023FY2021ended Dec 31, 2021filed Feb 9, 2022FY2020ended Dec 31, 2020filed Feb 17, 2021FY2019ended Dec 31, 2019filed Feb 26, 2020FY2018ended Dec 31, 2018filed Mar 13, 2019FY2017ended Dec 31, 2017filed Mar 7, 2018FY2016ended Dec 31, 2016filed Mar 21, 2017FY2015ended Dec 31, 2015filed Mar 8, 2016FY2014ended Dec 31, 2014filed Jun 12, 2015
Revenue000000000000
Cost of revenue————————————
Gross profit————————————
Research and development345102645445322419149722
Selling, general and administrative484937161111975551
Operating income(393)(151)(101)(70)(56)(43)(33)(26)(19)(14)(12)(23)
Other income (expense)34411511374(2)(1)(11)2
Pretax income(360)(110)(86)—————————
Income tax0000000000——
Net income(360)(110)(86)(69)(55)(39)(26)(22)(21)(15)(23)(22)
Diluted EPS ($)(3.19)(1.01)(0.91)(0.90)(0.71)———————
Diluted shares (millions)113109947777———————

Balance sheet

Viking Therapeutics, Inc balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 11, 2026FY2024ended Dec 31, 2024filed Feb 26, 2025FY2023ended Dec 31, 2023filed Feb 7, 2024FY2022ended Dec 31, 2022filed Feb 10, 2023FY2021ended Dec 31, 2021filed Feb 9, 2022FY2020ended Dec 31, 2020filed Feb 17, 2021FY2019ended Dec 31, 2019filed Feb 26, 2020FY2018ended Dec 31, 2018filed Mar 13, 2019FY2017ended Dec 31, 2017filed Mar 7, 2018FY2016ended Dec 31, 2016filed Mar 21, 2017FY2015ended Dec 31, 2015filed Mar 8, 2016FY2014ended Dec 31, 2014filed Jun 12, 2015
Cash and equivalents16627563726298259311
Short-term investments54087630711917621926727712———
Total current assets7169073671672112562843022214151
Total assets7169083681692112572843022215153
Total current liabilities772719229127596223
Long-term debt————————————
Total debt————————————
Total liabilities772820239127596725
Stockholders’ equity6398803481452022442772981389(22)
Shares outstanding (millions)1161121007878747372512410—

Cash flow statement

Viking Therapeutics, Inc cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 11, 2026FY2024ended Dec 31, 2024filed Feb 26, 2025FY2023ended Dec 31, 2023filed Feb 7, 2024FY2022ended Dec 31, 2022filed Feb 10, 2023FY2021ended Dec 31, 2021filed Feb 9, 2022FY2020ended Dec 31, 2020filed Feb 17, 2021FY2019ended Dec 31, 2019filed Feb 26, 2020FY2018ended Dec 31, 2018filed Mar 13, 2019FY2017ended Dec 31, 2017filed Mar 7, 2018FY2016ended Dec 31, 2016filed Mar 21, 2017FY2015ended Dec 31, 2015filed Mar 8, 2016FY2014ended Dec 31, 2014filed Jun 12, 2015
Operating cash flow(279)(88)(73)(48)(48)(22)(25)(19)(15)———
Capital expenditures————————————
Free cash flow (CFO − capex)————————————
Depreciation and amortization————————————
Share repurchases———7—————000
Dividends paid————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 16, 2024 to November 16, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$0
0 sales by 0 insiders; officers and directors $0
Bought, twelve months
$150K
1 purchases by 1 insider; officers and directors $150K
Sold, twelve months
$18M
16 sales by 4 insiders; officers and directors $18M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Aug 1, 2026Kelly-Gemmell Dorothy ElizabethDirectoraward6,333$0.00—6,333Aug 7, 2026
Jul 29, 2026Lian BrianPresident & CEO, Directoropen-market sale148,517$33.32$5M3MJul 29, 2026
Jul 29, 2026Zante GregChief Financial Officeropen-market sale21,217$33.47$710K212,204Jul 29, 2026
Jul 29, 2026Mancini MariannaChief Operating Officeropen-market sale18,217$33.47$610K422,760Jul 29, 2026
Jul 28, 2026Lian BrianPresident & CEO, Directoraward221,667$0.00—3MJul 29, 2026
Jul 28, 2026Zante GregChief Financial Officeraward31,667$0.00—233,421Jul 29, 2026
Jul 28, 2026Mancini MariannaChief Operating Officeraward31,667$0.00—440,977Jul 29, 2026
Mar 10, 2026Aubuchon Neil WilliamChief Commercial Officeropen-market buy4,475$33.50$150K4,475Mar 10, 2026
Jan 5, 2026Zante GregChief Financial Officeropen-market sale31,961$32.30$1M215,571Jan 5, 2026
Jan 5, 2026Zante GregChief Financial Officeropen-market sale13,900$33.38$464K201,671Jan 5, 2026
Jan 5, 2026Zante GregChief Financial Officeropen-market sale10,300$34.24$353K191,371Jan 5, 2026
Jan 5, 2026Zante GregChief Financial Officeropen-market sale1,500$32.09$48K189,891Jan 5, 2026
Jan 5, 2026Mancini MariannaChief Operating Officeropen-market sale31,961$32.29$1M434,890Jan 5, 2026
Jan 5, 2026Mancini MariannaChief Operating Officeropen-market sale13,600$33.37$454K421,290Jan 5, 2026
Jan 5, 2026Mancini MariannaChief Operating Officeropen-market sale10,500$34.22$359K410,790Jan 5, 2026
Jan 5, 2026Mancini MariannaChief Operating Officeropen-market sale1,600$35.07$56K409,190Jan 5, 2026
Jan 5, 2026Lian BrianPresident & CEO, Directoropen-market sale6,400$35.07$224K2MJan 5, 2026
Jan 5, 2026Lian BrianPresident & CEO, Directoropen-market sale53,279$33.38$2M3MJan 5, 2026
Jan 5, 2026Lian BrianPresident & CEO, Directoropen-market sale41,276$34.22$1M3MJan 5, 2026
Jan 5, 2026Lian BrianPresident & CEO, Directoropen-market sale132,454$32.29$4M3MJan 5, 2026
Jan 2, 2026Zante GregChief Financial Officeraward41,000$0.00—215,483Jan 5, 2026
Jan 2, 2026Zante GregChief Financial Officeraward32,049$0.00—247,532Jan 5, 2026
Jan 2, 2026Mancini MariannaChief Operating Officeraward41,000$0.00—434,802Jan 5, 2026
Jan 2, 2026Mancini MariannaChief Operating Officeraward32,049$0.00—466,851Jan 5, 2026
Jan 2, 2026Lian BrianPresident & CEO, Directoraward224,080$0.00—3MJan 5, 2026

Full insider history for Viking Therapeutics, Inc, or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
VIKING THERAPEUTICS, INC., CIK 1607678 on EDGAR
Extract generated
November 16, 2026
Withheld
none
Repaired
1 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: net income FY2014
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues
Cost of revenue: not filed
Gross profit: not filed
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: GeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: not filed
Total debt: not filed
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: not filed
Free cash flow (CFO − capex): not filed
Depreciation and amortization: not filed
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated November 16, 2026.

JSON file
/data/financials/VKTX.json